Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 w (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 w (Expand Search)
-
121
Spatial training decreases the association between Ndfip1 and Nedd4 and decreases endogenous Beclin 1 ubiquitination in the hippocampus.
Published 2023“…Endogenous Beclin 1 ubiquitination level is decreased in Nedd4 siRNA-transfected rats (t<sub>1,6</sub> = 5.78, <i>p</i> = 0.001). …”
-
122
-
123
-
124
-
125
Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice.
Published 2024“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n<sub>C57BL/6</sub> = 305 units from 5 recording sessions, n<sub>APP/PS1</sub> = 180 units from 4 recording sessions). …”
-
126
-
127
-
128
-
129
Spatial stability is decreased in APP/PS1 mice in both dCA1 and vCA1.
Published 2024“…<p>(A) In dCA1, stability score was significantly decreased in APP/PS1 mice relative to C57BL/6 mice (mean ± std: C57BL/6 = -0.009 ± 0.292, APP/PS1 = -0.1845 ± 0.256, p < 10<sup>−6</sup>, two-sided Wilcoxon rank-sum test, n<sub>C57BL/6</sub> = 295 units from 5 recording sessions, n<sub>APP/PS1</sub> = 167 units from 4 recording sessions). …”
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
139
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
140
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: